Plasmid-DNA vaccines encoding neoantigens, typically delivered by electroporation — the platform behind Geneos' and several academic programs.
Washington University School of Medicine is running a Phase I study of a personalized neoantigen-based DNA vaccine combined with retifanlimab (PD-1 blockade) in newly diagnosed, unmethylated glioblastoma. The trial assesses safety and immunogenicity, targeting a population with limited therapeutic options.
Washington University School of Medicine is assessing a personalized neoantigen-based DNA vaccine in newly diagnosed, unmethylated glioblastoma. This trial targets a difficult-to-treat brain cancer subtype, testing the feasibility and immunogenicity of DNA-based delivery in the CNS.
EurekAlert reports on how neoantigen dendritic cell vaccines are reshaping immunotherapy. This highlights the diversification of vaccine modalities, with dendritic cell-based approaches offering an alternative mechanism to mRNA/DNA vaccines for antigen presentation.
Washington University School of Medicine is recruiting for a Phase 1 study assessing the safety and feasibility of a personalized DNA vaccine in pediatric patients with recurrent or treatment-resistant central nervous system tumors. This trial targets a population with limited therapeutic options, focusing on the technical feasibility of delivering personalized DNA constructs in this demographic.
Geneos Therapeutics is conducting a Phase I/IIa single-arm study of GNOS-PV02, a personalized neoantigen DNA vaccine, combined with plasmid-encoded IL-12 (INO-9012) and pembrolizumab in advanced hepatocellular carcinoma (HCC). The trial is currently active but not recruiting, focusing on the combination of DNA-based immunization with immune checkpoint inhibition.